Surprising SanBio/Sumitomo Stroke Stumble Slams Stocks

 
• By Ian Haydock

Mesenchymal stem cell-based therapy's missed Phase IIb endpoint in stroke prompts both an assessment of future development plans and a precipitous fall in developers' stocks.

Memory loss and brain aging due to dementia and alzheimer's disease as a medical icon of a group of color changing autumn fall trees shaped as a human head losing leaves on a white background.
Phase II Failure For Novel Stroke Therapy • Source: Shutterstock

More from Japan

More from Focus On Asia